Platelet reactivity index after treatment of clopidogrel versus ticagrelor based on CYP2C19 genotypes among patients undergoing percutaneous coronary intervention: results of a randomized study

替卡格雷 医学 氯吡格雷 经皮冠状动脉介入治疗 CYP2C19型 传统PCI 内科学 心脏病学 普拉格雷 冠状动脉疾病 装载剂量 阿司匹林 心肌梗塞 新陈代谢 细胞色素P450
作者
Mohammed Ahmed Akkaif,Nur Aizati Athirah Daud,Dzul Azri Mohamed Noor,Abubakar Sha’aban,M J A Wahab,Muhamad Ali SK Abdul Kader,Baharudin Ibrahim
出处
期刊:European Heart Journal [Oxford University Press]
卷期号:44 (Supplement_1) 被引量:3
标识
DOI:10.1093/eurheartj/ehac779.120
摘要

Abstract Funding Acknowledgements Type of funding sources: None. Background Although clopidogrel is the basic drug for antiplatelet therapy in patients with coronary artery disease (CAD). However, loss of function (LOF) allelic variants located within the CYP2C19 gene may reduce the production of clopidogrel active metabolites and weaken the antiplatelet effect, increasing platelet rates reactivity and associated with increased rates of adverse events after percutaneous coronary intervention (PCI). Thus, drug regulatory authorities have warned of clopidogrel's reduced efficacy and suggested using alternative treatments (such as ticagrelor). However, in clinical practice, the strategy of genotype-guided selection for antiplatelet therapy has been limited by the lack of access to immediately available results. Purpose We sought to evaluate the effect of point-of-care genetic testing for CYP2C19 genotypes on the antiplatelet choice of therapy (i.e., clopidogrel vs ticagrelor), using platelet reactivity index (PRI) as a proxy of clinical outcome Method This study was a prospective, randomized, parallel design, an open-label investigation conducted among Malaysian patients with stable coronary artery disease (SCAD) undergoing PCI. Patients underwent rapid point-of-care genetic testing using the nested allele-specific multiplex PCR assay, which defines CYP2C19 genetic status within 3 hours, allowing patients to be genotyped on the same day before PCI. Patients who were carriers of at least one +LOF or -LOF (*2 or *3) allele was randomized to receive either clopidogrel [600mg loading dose (LD) - 75mg/day maintenance dose (MD)] or ticagrelor (180mg LD - 90mg MD). The induced platelet reactivity index (PRI) was assessed by Vasodilator-Associated Stimulated Phosphoprotein (VASP) Assay to whole blood at one standardized time point after 4 hours of LD. All patients were treated with aspirin. The primary endpoint of the study was the non-inferiority in platelet reactivity, measured as PRI, at 4 hours of clopidogrel vs ticagrelor in +LOF or -LOF allele carriers Result In 1638 SCAD patients, 94 underwent PCI and were genotyped and randomized to receive either clopidogrel (n=44) or ticagrelor (n=50). A total of 42 (44.68%) were carriers of at least one +LOF. PRI levels at 4 hours for clopidogrel vs ticagrelor 44 and 40, respectively (mean difference = 23.08; 95% CI: 17 to 30; p=<0.001); this will meet the primary endpoint of superiority in a non-inferiority. Ticagrelor significantly reduced PRI more than clopidogrel. The cross-tabulation of the response classification showed that ticagrelor is superior to clopidogrel based on the -LOF and +LOF (P= 0.005 and <0.001, respectively) Conclusion A rapid point-of-care genetic test using a nested allele-specific multiplex PCR assay can be used to personalize antiplatelet therapy and provides timely results for patients undergoing PCI. In addition, the results showed that ticagrelor was superior to clopidogrel in the level of platelet inhibition in both groups (+LOF or -LOF)

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
XxX发布了新的文献求助10
刚刚
wg发布了新的文献求助10
刚刚
1秒前
www关闭了www的文献求助
1秒前
2秒前
2秒前
佳洛父亲完成签到,获得积分10
2秒前
2秒前
初(*^▽^*)心的应助被斯文若血采纳,获得10
2秒前
英姑的应助被亦禾子啊采纳,获得10
2秒前
可爱多发布了新的文献求助10
2秒前
77wlr发布了新的文献求助10
3秒前
养火花发布了新的文献求助10
3秒前
3秒前
3秒前
科研通AI6.2的应助被211107采纳,获得10
3秒前
3秒前
科研通AI6.4的应助被211107采纳,获得10
3秒前
fantasy的应助被211107采纳,获得10
4秒前
4秒前
4秒前
4秒前
4秒前
小手冰凉发布了新的文献求助10
4秒前
4秒前
4秒前
5秒前
Kelly完成签到,获得积分10
5秒前
5秒前
学术顺利发布了新的文献求助10
5秒前
6秒前
英俊的铭的应助被弦弦弦采纳,获得10
6秒前
传奇3的应助被coldspringhao采纳,获得10
7秒前
7秒前
陆羽发布了新的文献求助10
8秒前
陆羽发布了新的文献求助10
8秒前
陆羽发布了新的文献求助10
8秒前
陆羽发布了新的文献求助10
8秒前
陆羽发布了新的文献求助10
8秒前
陆羽发布了新的文献求助10
8秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
The World Atlas of Wine 9th edition 1000
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
John McDowells Bildungstheorie 800
八旗制度の研究 600
What Else Can I Tell You?: A Pragmatic Study of English Rhetorical Questions as Discursive and Argumentative Acts 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8163835
求助须知:如何正确求助?哪些是违规求助? 9557925
关于积分的说明 21742693
捐赠科研通 7754454
什么是DOI,文献DOI怎么找? 3428350
关于科研通互助平台的介绍 2553034
邀请新用户注册赠送积分活动 2472982